Eli Lilly and Company (LLY) Q1 2024 Earnings Report

In Q1 2024, Eli Lilly reported a remarkable revenue growth of 26%, reaching $8.77 billion, predominantly driven by strong sales from its newly launched products Mounjaro and Zepbound. The quarter also saw significant operational achievements including key pipeline advancements, such as the Phase III success of tirzepatide for obstructive sleep apnea, alongside a promising capital strategy focused on expanding manufacturing capabilities. The company's net income increased to $2.24 billion, reflecting a robust earnings per share of $2.58, underscoring management's confidence in sustaining growth momentum throughout the year amid rising demands for incretin therapies and a strategic focus on innovative drug development.